OakChart

Immuron Limited ADR

IMRNHealthcare·Biotechnology·Australia·Nano·NASD·Nov 11 • 3:59 PM ET

0.9274+0.0274 (3.04%)
2026-11-11 22:45 CET
Market cap
7.26 USD m
Revenue, TTM
5.22 USD m
Net income, TTM
-2.49 USD m
Free cash flow, TTM
-2.16 USD m
EPS diluted, TTM
-0.34
P/E
-
Compare

Price

IMRN against its 20, 50 and 200-day averages
2050200earnings
1.001.502.0061.6M123.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMRNclose 0.9320-day 0.9250-day 1.11200-day 1.010.9352w high

53.4% under the 52-week high of 1.99 on 4 Sep 2026. 52-week low 0.68 on 30 Dec 2025. Last 15 sessions, 33.3% high to low

Volume 0.01× normal · the line is the 50-bar volume average

Profile

IMRN
52-week range, 19% of the way up
0.681.99

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group's R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

IPOMar 02, 2017
Beta1.18
ATR, 14d0.07
Rel volume0.01
Short float0.80%
Inst own0.97%

Snapshot

6 groups

Valuation

Index-
Market Cap7.48M
Enterprise Value1.23M
Income-2.49M
Sales5.22M
Book/sh0.96
Cash/sh0.77
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOMar 02, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S1.43
P/B0.97
P/C1.20
P/FCF-
EV/EBITDA-
EV/Sales0.24
Quick Ratio5.98
Current Ratio7.26
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.34
EPS next Y-
EPS next Q-0.00
EPS this Y98.15%
EPS next Y-
EPS next 5Y-
EPS past 3/5Y9.11% 21.57%
Sales past 3/5Y62.68% 116.97%
EPS Y/Y TTM42.44%
Sales Y/Y TTM10.41%
EPS Q/Q48.40%
Sales Q/Q18.70%
EarningsAug 27 AMC
EPS/Sales Surpr.-5.41% -9.85%

Ownership

Insider Own-
Insider Trans-
Inst Own0.97%
Inst Trans10.38%
ROA-31.68%
ROE-38.31%
ROIC-32.25%
Gross Margin64.54%
Oper. Margin-61.63%
Profit Margin-47.78%
SMA200.73%
SMA50-16.73%
SMA200-8.21%
Trades-

Technical

Shs Outstand8.07M
Shs Float3.25M
Short Float0.80%
Short Ratio0.01
Short Interest0.03M
52W High1.99 -53.40%
52W Low0.68 37.09%
Volatility8.31% 7.25%
ATR (14)0.07
RSI (14)45.54
Beta1.18
Rel Volume0.01
Avg Volume2.03M
Volume23,208

Performance

Perf Week8.73%
Perf Month-10.83%
Perf Quarter-17.93%
Perf Half Y4.20%
Perf YTD21.63%
Perf Year-42.75%
Perf 3Y-42.04%
Perf 5Y-73.65%
Perf 10Y-
Recom2.00
Target Price2.65
Prev Close0.90
Price0.93
Change %3.04%

Peers

Mkt cap
TickerCompanyMkt cap
SXTP60 Degrees Pharmaceuticals Inc1.83M
JAGXJaguar Health Inc6.44M
ACXPAcurx Pharmaceuticals Inc5.72M
ICCCImmucell Corp92.54M
SABSSAB Biotherapeutics Inc280.17M
MCRBSeres Therapeutics Inc15.29M
SPROSpero Therapeutics Inc59.40M
OGENOragenics Inc1.54M
SCNIScinai Immunotherapeutics Ltd ADR0.69M
ARMPArmata Pharmaceuticals Inc144.64M

News

latest 14 of 200
  • Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives (GlobeNewswire)
  • Emerging Growth Research Reports Continued Revenue Growth at Immuron (ACCESSWIRE)
  • Immuron continued quarterly sales growth (GlobeNewswire)
  • Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference (GlobeNewswire)
  • Travelan Phase 2 Study Results Published (GlobeNewswire)
  • IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years Whats Driving The Super Rally Today? (Stocktwits) +62.16%
  • Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement (InvestorsHub)
  • Immuron to launch PROIBS in the United States (GlobeNewswire)
  • Immuron Reports FY26 Preliminary Results (GlobeNewswire)
  • Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar (GlobeNewswire) -6.61%
  • Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year (GlobeNewswire) -5.04%
  • Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy (GlobeNewswire)
  • Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 (ACCESSWIRE) -5.29%
  • Immuron Double Digit 3Q Sales Growth (GlobeNewswire) +13.35%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S22026-08-27-0.004-0.004-0.0132.472.751
2026S12026-02-25-0.199--0.0132.972.89-
2025S22025-08-28-0.007--0.2972.14--
2025S12025-02-28-0.272--0.2882.49--
2024S22024-08-30-0.013--0.5621.70--
2027S1---0.003--3.291
2027S2---0.004--2.771

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2014FY-2.255-1.467-2.2550.981.20
2015FY1.250-1.2500.80-
2016FY1.715--2.1250.87-
2017FY-2.006-5.164-1.9311.091.13
2018FY-0.670--0.7131.34-
2019FY-2.192--0.9211.64-
2020FY-0.491--0.4451.86-
2024FY-0.020--0.7983.18-
2025FY-0.594--0.5854.774.73
2026FY-0.371-0.009-0.0205.545.39
2027FY--0.007--6.06

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027S1S2026-11-111003.293.293.29
2027S1S2026-11-041013.293.293.29
2027S1S2026-07-051003.363.363.36
2027S1S2026-04-211013.363.363.36
2027S1S2026-03-041103.963.963.96
2027S1S2025-11-111003.653.653.65
2027S1S2025-11-101003.653.653.65
2027S1S2025-11-091003.653.653.65
2027S1E2026-11-111000.000.000.00
2027S1E2026-11-041100.000.000.00
2027S1E2026-07-05100-0.01-0.01-0.01
2027S1E2026-04-21101-0.01-0.01-0.01
2027S1E2026-03-041100.000.000.00
2027S1E2025-11-11100-0.01-0.01-0.01

Estimate history

EPS, annual-0.713-0.921-0.445-1.131-0.364-0.447-0.798-0.585-0.336
Period201820192020202120222023202420252026
EPS, quarterly
Period
Sales, annual1.4281.7081.6880.1090.5551.2143.2134.7195.227
Period201820192020202120222023202420252026
Sales, quarterly
Period
Shares, annual3.5694.084.4575.6815.6955.6955.75.8498.071
Period201820192020202120222023202420252026
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue5.225.234.723.211.210.550.111.691.71
Cost of Goods Sold Incl. D&A1.851.881.671.030.330.180.040.460.48
Gross Profit3.373.343.052.190.880.380.071.231.23
Selling, General and Administrative Excl. Other6.596.557.447.845.213.325.783.504.97
Research and Development1.301.312.333.521.740.481.020.790.75
Other Operating Expense0.000.000.000.00-0.290.000.570.000.00
Operating Income-3.22-3.21-4.38-5.65-4.04-2.94-6.27-2.27-3.74
Interest Expense0.010.010.000.000.010.000.010.010.00
Unusual Expense0.000.000.000.370.350.01-0.120.000.01
Net Income Before Taxes-3.02-3.02-4.10-4.09-2.59-2.26-6.57-2.17-3.71
Income Taxes-0.53-0.53-0.72-0.50-0.26-0.19-0.32-0.21-0.38
Consolidated Net Income-2.49-2.49-3.38-4.55-2.55-2.07-6.25-1.96-3.33
Net Income From Continuing Operations-2.49-2.49-3.38-4.55-2.55-2.07-6.25-1.96-3.33
Net Income-2.49-2.49-3.38-4.55-2.55-2.07-6.25-1.96-3.33
EPS (Recurring)-0.31-0.34-0.59-0.75-0.40-0.36-1.15-0.44-0.92
EPS (Basic, Before Extraordinaries)-0.34-0.34-0.59-0.80-0.45-0.36-1.13-0.44-0.92
EPS (Diluted)-0.34-0.34-0.59-0.80-0.45-0.36-1.13-0.44-0.92
EBITDA--3.18-4.35-5.62-4.00-2.92-6.24-2.24-3.74
Non-Operating Income (Expense)0.200.200.291.931.800.70-0.410.120.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.020.020.030.000.070.071.58-0.360.96
Price To Sales Ratio1.641.512.134.299.4821.94246.5819.416.76
Gross Margin64.5463.9564.7168.0672.5468.4164.9772.6572.05
Operating Margin-61.63-61.39-92.88-175.90-332.49-530.47-5,772.19-134.62-218.94
Net Margin-47.78-47.71-71.58-141.49-209.81-373.01-5,751.60-116.23-195.04
Shares Outstanding8.078.075.855.705.695.695.684.464.08
Market Capitalization7.267.2610.1813.7911.5012.1927.5533.0911.42

Income statement, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S12023S22023S1
Total Revenue2.482.742.092.641.681.540.820.39
Cost of Goods Sold Incl. D&A0.851.000.750.880.520.510.230.10
Gross Profit1.631.741.341.761.161.030.600.29
Selling, General and Administrative Excl. Other3.343.253.613.864.363.482.632.57
Research and Development0.530.771.021.311.791.730.721.02
Other Operating Expense0.000.000.000.000.000.00-0.290.00
Operating Income-1.71-1.51-2.27-2.11-3.20-2.45-1.75-2.29
Interest Expense0.010.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.00-0.020.380.310.04
Net Income Before Taxes-1.49-1.54-2.25-1.84-2.74-1.36-1.24-1.35
Income Taxes-0.25-0.28-0.52-0.19-0.36-0.14-0.18-0.09
Consolidated Net Income-1.24-1.26-1.73-1.65-3.20-1.35-1.22-1.33
Net Income From Continuing Operations-1.24-1.26-1.73-1.65-3.20-1.35-1.22-1.33
Net Income-1.24-1.26-1.73-1.65-3.20-1.35-1.22-1.33
EPS (Recurring)-0.15-0.18-0.30-0.29-0.56-0.19-0.18-0.23
EPS (Basic, Before Extraordinaries)-0.15-0.18-0.30-0.29-0.56-0.24-0.21-0.23
EPS (Diluted)-0.15-0.18-0.30-0.29-0.56-0.24-0.21-0.23
Non-Operating Income (Expense)0.23-0.020.030.270.451.470.820.98
Stock Option Compensation Expense0.020.000.010.03-0.010.030.04
Price To Sales Ratio1.641.082.142.254.294.529.4615.28
Gross Margin65.7863.4264.0266.5268.9567.0972.1773.32
Operating Margin-68.80-55.14-108.82-79.74-191.15-159.40-211.78-585.01
Net Margin-49.90-45.86-82.83-62.31-190.94-88.01-148.08-338.97
Shares Outstanding8.078.175.855.735.705.695.695.69
Market Capitalization7.266.2310.189.7413.7910.6811.5011.85

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments6.253.847.7912.6415.2018.802.243.593.49
Short Term Receivables0.981.260.930.280.460.250.230.681.24
Inventories1.581.161.060.560.220.220.550.380.37
Other Current Assets0.180.300.060.110.390.060.020.030.10
Total Current Assets8.986.569.8313.5916.2819.333.044.695.21
Net Property, Plant & Equipment0.130.070.100.130.160.030.050.010.02
Total Investments and Advances0.000.000.000.110.000.000.000.000.00
Intangible Assets0.00--------
Other Assets0.000.000.450.810.660.951.191.311.60
Total Assets9.116.6410.3914.6417.0920.314.276.016.83
Short Term Debt Incl. Current Port. of LT Debt0.000.000.030.030.020.020.030.000.00
Accounts Payable0.610.660.430.530.500.080.110.500.16
Other Current Liabilities0.620.631.340.920.510.750.220.340.43
Total Current Liabilities1.241.291.801.481.030.840.360.840.59
Long Term Debt0.000.000.090.100.120.000.010.00-
Provision for Risks Charges0.030.010.010.000.000.030.020.010.00
Other Liabilities0.110.050.000.000.000.000.000.000.00
Total Liabilities1.381.351.901.581.150.870.380.850.59
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity7.745.298.4913.0615.9419.443.895.166.24
Total Shareholders Equity7.745.298.4913.0615.9419.443.895.166.24
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity7.745.298.4913.0615.9419.443.895.166.24
Total Liabilities & Stockholders Equity9.116.6410.3914.6417.0920.314.276.016.83
Book Value Per Share0.960.901.492.292.803.420.871.261.75
Tangible Book Value Per Share0.960.901.492.292.803.420.871.261.75
Price to Book Ratio0.941.561.150.880.761.428.522.268.43
Return on Assets-31.67-39.69-36.34-16.06-11.07-50.87-38.18-51.89-35.39
Return on Equity-38.30-49.04-42.20-17.57-11.70-53.61-43.39-58.47-41.37
Return on Invested Capital-32.24-63.88-53.01-19.36-12.89-32.16-50.33-64.57-
Quick Ratio5.984.194.878.8215.5322.696.995.138.16
Current Ratio7.265.095.469.2015.7522.968.545.598.78

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income--2.49-3.38-4.55-2.55-2.07-6.25-1.96-3.33
Depreciation-0.030.030.030.030.020.030.030.00
Other Funds (Non Cash)0.300.290.190.93-0.10-0.032.04-0.310.99
Funds from Operations-2.26-2.18-3.16-3.59-2.62-2.08-4.18-2.24-2.33
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.10-0.73-0.060.94-0.201.140.121.05
Cash from Operating Activities-2.15-2.08-3.89-3.64-1.67-2.27-3.04-2.12-1.29
Capital Expenditures-0.00-0.000.00-0.00-0.01-0.01-0.00-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments2.132.06-1.970.00-1.840.000.000.000.00
Purchase of Investments0.000.00-1.970.00-1.840.000.000.000.00
Sale Or Maturity of Investments2.132.060.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities2.132.05-1.97-0.00-1.84-0.01-0.00-0.00-0.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.684.510.180.020.000.0019.791.061.48
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.684.510.180.020.000.0019.791.061.48
Proceedsfrom Stock Options4.684.510.180.020.000.0019.791.061.48
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-0.250.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.160.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.160.000.00
Net Financing Active Other Cash Flow-0.09-0.080.000.000.000.000.000.000.00
Other Financing Activities Uses-0.09-0.080.000.000.000.000.000.000.00
Cash from Financing Activities4.564.400.130.01-0.02-0.0319.760.791.48
Exchange Rate Effect-0.19-0.180.010.030.210.18-0.450.080.09
Net Change in Cash4.354.19-5.72-3.61-3.33-2.1316.25-1.250.28
Free Cash Flow-2.16-2.08-3.89-3.64-1.68-2.28-3.05-2.12-1.29
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S1
Cash & Short Term Investments6.256.673.844.797.7911.20
Short Term Receivables0.981.681.261.390.930.38
Inventories1.581.491.160.941.061.11
Other Current Assets0.180.110.300.160.060.24
Total Current Assets8.989.956.567.289.8312.93
Net Property, Plant & Equipment0.130.140.070.080.100.12
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.00----
Other Assets0.000.000.000.170.450.52
Total Assets9.1110.096.647.5310.3913.57
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.030.03
Accounts Payable0.931.001.000.801.431.14
Other Current Liabilities0.300.240.290.270.350.35
Total Current Liabilities1.241.241.291.071.801.52
Long Term Debt0.000.000.000.060.090.09
Other Liabilities0.110.120.050.010.000.00
Total Liabilities1.381.371.351.131.901.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity7.748.725.296.408.4911.96
Total Shareholders Equity7.748.725.296.408.4911.96
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity7.748.725.296.408.4911.96
Total Liabilities & Stockholders Equity9.1110.096.647.5310.3913.57
Book Value Per Share0.961.070.901.121.492.10
Tangible Book Value Per Share0.961.070.901.121.492.10
Price to Book Ratio0.940.841.561.141.150.82
Return on Assets-31.68-33.89-39.65-45.93-36.40-17.61
Return on Equity-38.31-39.51-49.00-52.79-42.27-19.52
Return on Invested Capital-15.99-14.42-32.72-25.47-37.32-11.23
Quick Ratio5.986.834.195.924.877.79
Current Ratio7.268.045.096.805.468.52

Cash flow, quarterly

Currency USD, millions
Metric2026S22026S12025S22025S12024S22024S1
Other Funds (Non Cash)1.92-1.622.79-2.610.830.10
Funds from Operations-0.64-1.62-0.49-2.61-2.39-1.21
Cash from Operating Activities-0.53-1.62-1.20-2.61-2.45-1.21
Capital Expenditures-0.00-0.000.000.00-0.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.141.99-1.930.000.000.00
Purchase of Investments0.000.00-1.930.000.000.00
Sale Or Maturity of Investments0.141.990.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.141.99-1.930.00-0.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.254.420.170.000.020.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.254.420.170.000.020.00
Proceedsfrom Stock Options0.254.420.170.000.020.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.090.000.000.000.000.00
Other Financing Activities Uses-0.090.000.000.000.000.00
Cash from Financing Activities0.154.410.16-0.030.02-0.01
Exchange Rate Effect-0.11-0.07-0.030.040.08-0.05
Net Change in Cash-0.354.69-3.01-2.59-2.35-1.27
Free Cash Flow-0.53-1.63-1.20-2.61-2.45-1.21

Revenue breakdown

ProIBS2026: 57.77K
Protectyn2025: 31.45K 2026: 14.78K
Travelan2025: 4.69M 2026: 5.16M
Australia2025: 3.40M 2026: 3.92M
Canada2025: 245.21K 2026: 112.30K
United States2025: 1.07M 2026: 1.20M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.80%0.0M3.3M2.03M
2026-10-152.04%0.1M3.3M2.03M
2026-09-301.90%0.1M3.3M2.07M
2026-09-153.56%0.1M3.3M2.09M
2026-08-311.05%0.0M3.3M41.72K
2026-08-141.23%0.0M3.3M238.41K
2026-07-311.11%0.0M3.3M243.13K
2026-07-152.43%0.1M3.3M249.81K
2026-06-302.27%0.1M3.3M238.54K
2026-06-154.40%0.1M3.3M232.02K
2026-05-2916.39%0.5M3.3M226.16K
2026-05-150.81%0.0M3.3M31.04K
2026-04-300.60%0.0M3.3M26.78K
2026-04-150.36%0.0M3.3M23.89K
2026-03-310.17%0.0M3.3M40.07K
2026-03-130.90%0.0M3.3M47.23K
2026-02-270.82%0.0M3.3M451.13K
2026-02-130.50%0.0M3.3M454.72K
2026-01-300.59%0.0M3.3M569.16K
2026-01-150.95%0.0M3.3M565.46K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-10-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-23424B5SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-10-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-16SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-09-2420-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2026-06-30SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-09-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-04SEC
2026-08-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-28SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-07-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-27SEC
2026-07-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-21SEC
2026-07-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-20SEC
2026-07-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-16SEC
2026-07-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-06SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-23SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-18SEC
2026-05-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-28SEC
2026-05-143Initial statement of beneficial ownership of securities2026-03-18SEC
2026-05-143Initial statement of beneficial ownership of securities2026-03-18SEC
2026-05-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-08SEC
2026-05-043Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-04-293Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC0.53%
UBS Group AG0.28%
HRT FINANCIAL LP0.25%
BNP PARIBAS FINANCIAL MARKETS0.06%
RHUMBLINE ADVISERS0.05%
MORGAN STANLEY0.02%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
-

OakChart. IMRN. Cached 15 minutes.

Some panels did not load: ratings, insider.